Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the signing of an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead created to ...

Arrowhead Pharmaceuticals strikes a $130M+ deal with Sanofi for plozasiran in Greater China, targeting high triglyceride ...

US RNA interference (RNAi)specialist Arrowhead Pharmaceuticals (Nasdaq: ARWR) today announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with France ...

Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

Bicycle Therapeutics BCYC underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below summarizes their recent ratings ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

Sarepta Therapeutics announced a layoff of 493 employees, including 80 in Franklin County, amid restructuring efforts and criticism from the FDA.

COLUMBUS, Ohio (WCMH) — Sarepta Therapeutics announced it is laying off nearly 500 employees this week, including 80 at its Easton location. According to a mass layoff notice filed with the s… ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular dystrophy over safety issues, even as patients and investors expressed ...

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on Elevidys.

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a muscular dystrophy patient who received a different, experimental treatment ...